Cargando…

Surgical treatment of non-cystic fibrosis bronchiectasis in Central Europe

BACKGROUND: Bronchiectasis is a mostly irreversible bronchial dilatation induced by the destruction of elastic and muscular fibers of the bronchial wall. Surgical treatment is usually reserved for focal disease, and whenever complications, like hemoptysis or secondary aspergilloma, arise. In this st...

Descripción completa

Detalles Bibliográficos
Autores principales: Selman, Alaa, Merhej, Hayan, Nakagiri, Tomoyuki, Zinne, Norman, Goecke, Tobias, Haverich, Axel, Zardo, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575831/
https://www.ncbi.nlm.nih.gov/pubmed/34795933
http://dx.doi.org/10.21037/jtd-21-879
_version_ 1784595754652794880
author Selman, Alaa
Merhej, Hayan
Nakagiri, Tomoyuki
Zinne, Norman
Goecke, Tobias
Haverich, Axel
Zardo, Patrick
author_facet Selman, Alaa
Merhej, Hayan
Nakagiri, Tomoyuki
Zinne, Norman
Goecke, Tobias
Haverich, Axel
Zardo, Patrick
author_sort Selman, Alaa
collection PubMed
description BACKGROUND: Bronchiectasis is a mostly irreversible bronchial dilatation induced by the destruction of elastic and muscular fibers of the bronchial wall. Surgical treatment is usually reserved for focal disease, and whenever complications, like hemoptysis or secondary aspergilloma, arise. In this study, we report our experience and outcomes in surgical bronchiectasis management between 2016 and 2020. METHODS: We retrospectively searched our database for patients admitted for surgical treatment of bronchiectasis between 2016 and 2020. All records were screened for pre-surgical management. Age, gender, distribution of bronchiectatic lesions, type of surgery, perioperative complications, chest tube duration, length of hospital stay as well as 30-day-mortality were recorded, and a brief follow-up was made. RESULTS: A total of n=34 patients underwent pulmonary resection with bronchiectasis. Mean age on admission was 56.2±15.1 years and n=21 patients (62%) were female. In n=23 cases the right lung was affected, in n=9 cases the left side and in two cases both lungs. Indications for surgery included persistent major alterations after conservative therapy (n=9), massive hemoptysis (n=4), and full-blown “destroyed lobe” (n=7). All patients received anatomical lung resection (n=21 lobectomies, n=2 bilobectomies and n=11 segmentectomies), either by uniportal video assisted thoracoscopic surgery (n=28) or by lateral thoracotomy (n=6). Average length of hospital stay was 7.9±6.3 days; one patient died on POD 7 due to myocardial infarction. CONCLUSIONS: In spite of a decreasing number of patients with bronchiectasis referred to surgery due to improvements in preventing and managing the disease, pulmonary resection still plays a significant role in treating this pathology in Central Europe. Surgery remains a viable approach for localized forms of bronchiectasis, and the only option in treating acute deterioration and complications like massive hemoptysis.
format Online
Article
Text
id pubmed-8575831
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-85758312021-11-17 Surgical treatment of non-cystic fibrosis bronchiectasis in Central Europe Selman, Alaa Merhej, Hayan Nakagiri, Tomoyuki Zinne, Norman Goecke, Tobias Haverich, Axel Zardo, Patrick J Thorac Dis Original Article BACKGROUND: Bronchiectasis is a mostly irreversible bronchial dilatation induced by the destruction of elastic and muscular fibers of the bronchial wall. Surgical treatment is usually reserved for focal disease, and whenever complications, like hemoptysis or secondary aspergilloma, arise. In this study, we report our experience and outcomes in surgical bronchiectasis management between 2016 and 2020. METHODS: We retrospectively searched our database for patients admitted for surgical treatment of bronchiectasis between 2016 and 2020. All records were screened for pre-surgical management. Age, gender, distribution of bronchiectatic lesions, type of surgery, perioperative complications, chest tube duration, length of hospital stay as well as 30-day-mortality were recorded, and a brief follow-up was made. RESULTS: A total of n=34 patients underwent pulmonary resection with bronchiectasis. Mean age on admission was 56.2±15.1 years and n=21 patients (62%) were female. In n=23 cases the right lung was affected, in n=9 cases the left side and in two cases both lungs. Indications for surgery included persistent major alterations after conservative therapy (n=9), massive hemoptysis (n=4), and full-blown “destroyed lobe” (n=7). All patients received anatomical lung resection (n=21 lobectomies, n=2 bilobectomies and n=11 segmentectomies), either by uniportal video assisted thoracoscopic surgery (n=28) or by lateral thoracotomy (n=6). Average length of hospital stay was 7.9±6.3 days; one patient died on POD 7 due to myocardial infarction. CONCLUSIONS: In spite of a decreasing number of patients with bronchiectasis referred to surgery due to improvements in preventing and managing the disease, pulmonary resection still plays a significant role in treating this pathology in Central Europe. Surgery remains a viable approach for localized forms of bronchiectasis, and the only option in treating acute deterioration and complications like massive hemoptysis. AME Publishing Company 2021-10 /pmc/articles/PMC8575831/ /pubmed/34795933 http://dx.doi.org/10.21037/jtd-21-879 Text en 2021 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Selman, Alaa
Merhej, Hayan
Nakagiri, Tomoyuki
Zinne, Norman
Goecke, Tobias
Haverich, Axel
Zardo, Patrick
Surgical treatment of non-cystic fibrosis bronchiectasis in Central Europe
title Surgical treatment of non-cystic fibrosis bronchiectasis in Central Europe
title_full Surgical treatment of non-cystic fibrosis bronchiectasis in Central Europe
title_fullStr Surgical treatment of non-cystic fibrosis bronchiectasis in Central Europe
title_full_unstemmed Surgical treatment of non-cystic fibrosis bronchiectasis in Central Europe
title_short Surgical treatment of non-cystic fibrosis bronchiectasis in Central Europe
title_sort surgical treatment of non-cystic fibrosis bronchiectasis in central europe
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575831/
https://www.ncbi.nlm.nih.gov/pubmed/34795933
http://dx.doi.org/10.21037/jtd-21-879
work_keys_str_mv AT selmanalaa surgicaltreatmentofnoncysticfibrosisbronchiectasisincentraleurope
AT merhejhayan surgicaltreatmentofnoncysticfibrosisbronchiectasisincentraleurope
AT nakagiritomoyuki surgicaltreatmentofnoncysticfibrosisbronchiectasisincentraleurope
AT zinnenorman surgicaltreatmentofnoncysticfibrosisbronchiectasisincentraleurope
AT goecketobias surgicaltreatmentofnoncysticfibrosisbronchiectasisincentraleurope
AT haverichaxel surgicaltreatmentofnoncysticfibrosisbronchiectasisincentraleurope
AT zardopatrick surgicaltreatmentofnoncysticfibrosisbronchiectasisincentraleurope